Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era

Nabil F Saba; Pooja Vijayvargiya; Jan B Vermorken; Juan P Rodrigo; Stefan M Willems; Nina Zidar; Remco de Bree; Antti Mäkitie; Greg T Wolf; Athanassios Argiris; Yong Teng; Alfio Ferlito

doi:10.3390/cancers14051202

Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era

Nabil F Saba, Pooja Vijayvargiya, Jan B Vermorken, Juan P Rodrigo, Stefan M Willems, Nina Zidar, Remco de Bree, Antti Mäkitie, Greg T Wolf, Athanassios Argiris, Yong Teng, Alfio Ferlito

Research output: Contribution to journal › Article › Academic › peer-review

8 Downloads (Pure)

Abstract

Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition.

Original language	English
Article number	1202
Journal	Cancers
Volume	14
Issue number	5
DOIs	https://doi.org/10.3390/cancers14051202
Publication status	Published - 25 Feb 2022

Keywords

Angiogenesis
Immunotherapy
SCCHN
Tumor microenvironment
VEGF

Access to Document

10.3390/cancers14051202Licence: CC BY

cancers-14-01202-v2Final published version, 1.41 MBLicence: CC BY

Cite this

@article{e0f6ea2279e940809fd689d1dcc8f818,

title = "Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era",

abstract = "Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition.",

keywords = "Angiogenesis, Immunotherapy, SCCHN, Tumor microenvironment, VEGF",

author = "Saba, {Nabil F} and Pooja Vijayvargiya and Vermorken, {Jan B} and Rodrigo, {Juan P} and Willems, {Stefan M} and Nina Zidar and {de Bree}, Remco and Antti M{\"a}kitie and Wolf, {Greg T} and Athanassios Argiris and Yong Teng and Alfio Ferlito",

note = "Funding Information: This article was written by the members and invitees of the International Head and Neck Scientific Group (www.IHNSG.com, accessed on 16 February 2022). Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = feb,

day = "25",

doi = "10.3390/cancers14051202",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

TY - JOUR

T1 - Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck

T2 - Opportunities in the Immunotherapy Era

AU - Saba, Nabil F

AU - Vijayvargiya, Pooja

AU - Vermorken, Jan B

AU - Rodrigo, Juan P

AU - Willems, Stefan M

AU - Zidar, Nina

AU - de Bree, Remco

AU - Mäkitie, Antti

AU - Wolf, Greg T

AU - Argiris, Athanassios

AU - Teng, Yong

AU - Ferlito, Alfio

N1 - Funding Information: This article was written by the members and invitees of the International Head and Neck Scientific Group (www.IHNSG.com, accessed on 16 February 2022). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/2/25

Y1 - 2022/2/25

N2 - Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition.

AB - Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition.

KW - Angiogenesis

KW - Immunotherapy

KW - SCCHN

KW - Tumor microenvironment

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85125179271&partnerID=8YFLogxK

U2 - 10.3390/cancers14051202

DO - 10.3390/cancers14051202

M3 - Article

C2 - 35267508

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 5

M1 - 1202

ER -

Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this